A Case of Scalp Psoriasis Resistant to Ixekizumab Treated with Bimekizumab

Overview

Journal JAAD Case Rep

Specialty Dermatology

Date 2023 Aug 3

PMID 37534105

Authors

Matteo Megna

Vincenzo Picone

Virginia Ventura

Fabrizio Martora

Angelo Ruggiero

Gabriella Fabbrocini

Teresa Battista

Affiliations

Soon will be listed here.

Citing Articles

Palmoplantar Psoriasis Resistant to Adalimumab Successfully Treated with Bimekizumab.

Trovato E, Dragotto M, Capalbo E, Rubegni P Dermatol Pract Concept. 2024; 14(4).

PMID: 39652915 PMC: 11619968. DOI: 10.5826/dpc.1404a244.

References

Gottlieb A, Warren R, Augustin M, Garcia L, Cioffi C, Peterson L . Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM): A Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Reported Data from the BE RADIANT Phase 3b Trial. Adv Ther. 2021; 38(10):5253-5269. PMC: 8478739. DOI: 10.1007/s12325-021-01836-1. View

Ruggiero A, Picone V, Martora F, Fabbrocini G, Megna M . Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence. Clin Cosmet Investig Dermatol. 2022; 15:1649-1658. PMC: 9392468. DOI: 10.2147/CCID.S364640. View

Ruggiero A, Potestio L, Camela E, Fabbrocini G, Megna M . Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge. Psoriasis (Auckl). 2022; 12:127-137. PMC: 9189155. DOI: 10.2147/PTT.S367744. View

Sarma N . Evidence and Suggested Therapeutic Approach in Psoriasis of Difficult-to-treat Areas: Palmoplantar Psoriasis, Nail Psoriasis, Scalp Psoriasis, and Intertriginous Psoriasis. Indian J Dermatol. 2017; 62(2):113-122. PMC: 5363132. DOI: 10.4103/ijd.IJD_539_16. View

Narcisi A, Valenti M, Cortese A, Toso F, Pavia G, Gargiulo L . Anti-IL17 and anti-IL23 biologic drugs for scalp psoriasis: A single-center retrospective comparative study. Dermatol Ther. 2021; 35(2):e15228. DOI: 10.1111/dth.15228. View

Gordon K, Foley P, Krueger J, Pinter A, Reich K, Vender R . Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021; 397(10273):475-486. DOI: 10.1016/S0140-6736(21)00126-4. View

Lauro W, Picone V, Abategiovanni L, Vastarella M, Gallo L, Fabbrocini G . A case of psoriatic alopecia secondary to certolizumab pegol: clinical and trichoscopic evaluation. Int J Dermatol. 2022; 62(2):e70-e72. DOI: 10.1111/ijd.16275. View

Reich K, Papp K, Blauvelt A, Langley R, Armstrong A, Warren R . Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021; 397(10273):487-498. DOI: 10.1016/S0140-6736(21)00125-2. View

Warren R, Blauvelt A, Bagel J, Papp K, Yamauchi P, Armstrong A . Bimekizumab versus Adalimumab in Plaque Psoriasis. N Engl J Med. 2021; 385(2):130-141. DOI: 10.1056/NEJMoa2102388. View

10.

Parisi R, Iskandar I, Kontopantelis E, Augustin M, Griffiths C, Ashcroft D . National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020; 369:m1590. PMC: 7254147. DOI: 10.1136/bmj.m1590. View

11.

Camela E, Ocampo-Garza S, Cinelli E, Villani A, Fabbrocini G, Megna M . Therapeutic update of biologics and small molecules for scalp psoriasis: a systematic review. Dermatol Ther. 2021; 34(2):e14857. DOI: 10.1111/dth.14857. View

12.

Egeberg A, Andersen Y, Halling-Overgaard A, Alignahi F, Thyssen J, Burge R . Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis. J Eur Acad Dermatol Venereol. 2019; 34(1):39-46. DOI: 10.1111/jdv.15920. View

13.

Asahina A, Okubo Y, Morita A, Tada Y, Igarashi A, Langley R . Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study. Dermatol Ther (Heidelb). 2023; 13(3):751-768. PMC: 9984664. DOI: 10.1007/s13555-022-00883-y. View